Trials / Recruiting
RecruitingNCT05982119
Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study
Gait Analysis Parameter, Stair Climbing and Upper Limb Evaluation in Patients With Muscular Pathology and in Control Subjects: The ActiLiège Next Study
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Centre Hospitalier Universitaire de Liege · Academic / Other
- Sex
- All
- Age
- 1 Year – 80 Years
- Healthy volunteers
- Accepted
Summary
The objective of the ActiLiège Next study is to collect longitudinal data from patients and control subjects using a wearable magneto-inertial device. By collecting natural history data in various neuromuscular disorders (Duchenne Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy, Myotonic Dystrophy 1, Charcot-Marie-Tooth, Centronuclear Myopathy, Congenital Muscular Dystrophy), we aim to validate digital outcome measures to continuously assess motor function in real-life.
Conditions
- Duchenne Muscular Dystrophy
- Fascioscapulohumeral Muscular Dystrophy
- Myotonic Dystrophy 1
- Charcot-Marie-Tooth
- Centronuclear Myopathy
- Congenital Muscular Dystrophy
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | ActiMyo/Syde | The two "watches" can be worn as wristwatch or placed near the ankle and on the wheelchair. * Patients with DMD or FKRP mutation will wear the ActiMyo°/Syde° during 3 months at baseline and then for one month every 3 months. * Patient with FSHD, DM1, CMT, CNM will wear the ActiMyo°/Syde° will wear the ActiMyo/Syde° during 3 months at baseline and then for one month every 6 months. * Control subjects \>4years will wear the ActiMyo°/Syde° during one month after inclusion and during one other month 11 months after inclusion. * Control subjects \<4years will wear the ActiMyo°/Syde° during one month after inclusion and during one other month every 6months after inclusion. |
Timeline
- Start date
- 2020-07-10
- Primary completion
- 2026-03-01
- Completion
- 2026-03-01
- First posted
- 2023-08-08
- Last updated
- 2025-05-20
Locations
8 sites across 7 countries: Belgium, Czechia, Egypt, Hungary, Poland, Romania, Slovenia
Source: ClinicalTrials.gov record NCT05982119. Inclusion in this directory is not an endorsement.